Generac Holdings (GNRC) is a Top-Ranked Growth Stock: Should You Buy?

Generac Holdings (GNRC) is highlighted as a potential growth investment, currently holding a Zacks #3 (Hold) Rank but boasting a B VGM Score and B Growth Style Score. The company is projected for 4.8% year-over-year earnings growth, with fiscal 2025 earnings estimates recently revised upwards by analysts to $7.62 per share, and a history of 19.2% average earnings surprises. This combination of strong growth indicators and positive revisions suggests GNRC warrants consideration for growth-focused portfolios, according to Zacks' methodology.

Analysis

Generac Holdings (GNRC) presents a nuanced investment profile, characterized by a neutral Zacks #3 (Hold) rank that contrasts with strong underlying growth indicators. The company scores favorably with a 'B' for both its composite VGM Score and its specific Growth Style Score. While current fiscal year earnings growth is projected at a modest 4.8%, the forward outlook is improving significantly. For fiscal 2025, six analysts have revised earnings estimates upwards within the last 60 days, pushing the Zacks Consensus Estimate up by $0.22 to $7.62 per share. This positive revision momentum is complemented by a historical track record of consistently exceeding expectations, as evidenced by an average earnings surprise of +19.2%. The combination of these positive fundamental signals, particularly the upward revisions for FY2025, suggests an improving operational outlook that may not yet be fully reflected in its current neutral stock rating.

Key Decisions for Investors

• Growth-oriented investors should consider the positive underlying signals, such as the 'B' Growth Score and upward FY2025 earnings revisions, which may present an opportunity ahead of a potential ratings upgrade.
• Investors should monitor for a change in the Zacks Rank from #3 (Hold) to a #2 (Buy) or #1 (Strong Buy), as this would align the rating with the strong growth metrics and serve as a significant positive catalyst according to the methodology presented.
• Given the current #3 (Hold) rank, a patient approach may be warranted, as the positive forward-looking indicators may take time to translate into significant share price appreciation.